The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...
Drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a share-price ...
Citi analyst Geoff Meacham maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $65.00. The ...
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report).
The ERISA Industry Committee, along with two other industry groups, is seeking the dismissal of the drugmaker’s PRT lawsuit ...
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce ...
Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...
In an amicus brief, several advocacy groups warned that letting the lawsuit proceed past a motion to dismiss could open the ...
R Squared Ltd purchased a new position in Bristol-Myers Squibb (NYSE:BMY – Free Report) in the 4th quarter, according to its ...
To get a sense of who is truly in control of Bristol-Myers Squibb Company ( NYSE:BMY ), it is important to understand the ownership structure of the business. And the group that holds the biggest ...